Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Pembrolizumab treatment for melanoma is “broadly effective”

Study results support the use of pembrolizumab in patients with advanced melanoma.



Advanced melanoma (pictured) patients have few options if ipilimumab treatment fails, so now researchers have characterised tumour response to the new therapy pembrolizumab 

Patients with advanced melanoma have limited treatment options, particularly if their disease has progressed after treatment with ipilimumab. 

However, pembrolizumab, an “immune checkpoint inhibitor”, was approved by the National Institute for Health and Care Excellence in 2015 for use on the NHS for both ipilimumab-treated and naive patients with advanced melanoma. 

Researchers have now analysed survival and tumour response from pooled phase I results in 655 patients with advanced melanoma. The overall objective response rate (ORR) was 33% and the 12-month progression-free survival rate was 35%; median overall survival was 23 months. The ORR was slightly lower in patients who had previously received ipilimumab, but differences in baseline characteristics may be the cause, say the researchers. 

Reporting in JAMA (online, 19 April 2016)[1], the team say the results support the “broad activity” of pembrolizumab in patients with advanced melanoma.

Citation: The Pharmaceutical Journal DOI: 10.1211/CP.2016.20201079

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Melanoma

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.